A phase I/2 open label study of Nivolumab monotherapy or Nivolmab combined with Ipilmumab in subjects with advanced or metastatic solid tumors.
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
November 1, 2013
End Date
November 30, 2024
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
November 1, 2013
End Date
November 30, 2024